Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,198 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 1,198 shares of the company’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total value of $510,755.32. Following the completion of the sale, the chief financial officer owned 49,658 shares in the company, valued at $21,171,191.72. The trade was a 2.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total value of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total value of $84,952.83.

Natera Trading Up 2.7%

Shares of NASDAQ:NTRA opened at $436.00 on Friday. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41. The company has a market capitalization of $62.85 billion, a PE ratio of -320.59 and a beta of 1.50. The business has a 50 day moving average of $375.27 and a two-hundred day moving average of $265.54.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.74) EPS. Equities research analysts predict that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on NTRA. Rothschild & Co Redburn began coverage on shares of Natera in a report on Tuesday, September 8th. They set a “buy” rating and a $385.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Wells Fargo & Company lifted their price objective on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Canaccord Genuity Group upped their price objective on shares of Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Finally, BTIG Research increased their target price on shares of Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Investors Weigh In On Natera

Institutional investors have recently added to or reduced their stakes in the stock. Trust Co. of Vermont acquired a new position in Natera during the second quarter worth $26,000. Elevation Wealth Partners LLC purchased a new position in Natera during the second quarter valued at $30,000. Continuum Advisory LLC acquired a new stake in shares of Natera in the second quarter valued at about $33,000. International Assets Investment Management LLC grew its position in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares during the period. Finally, Rakuten Securities Inc. acquired a new stake in shares of Natera in the second quarter valued at about $35,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.